Epstein-Barr virus (EBV) infection in B-cell non-Hodgkin's lymphomas in children: Virus latency and its correlation with CD21 and CD23 molecules

Folia Histochemica et Cytobiologica

Volumn 45, Issue 3, 2007, Pages 169-179

  Kasprzak, Aldona ^a   Spachacz, Rafał ^a   Wachowiak, Jacek ^a   Stefańska, Katarzyna ^a   Zabel, Maciej ^a,b  

^a POZNAN UNIVERSITY OF MEDICAL SCIENCES   (Poland)

^b WROCLAW MEDICAL UNIVERSITY   (Poland)

Author keywords

B cell non Hodgkin's lymphoma; CD21 and CD23; EBV tissue markers; Hybridization in situ; Immunocytochemistry; ImmunoMax technique; PCR

Indexed keywords

CD23 ANTIGEN; COMPLEMENT COMPONENT C3D RECEPTOR; EPSTEIN BARR VIRUS ANTIGEN; EPSTEIN BARR VIRUS ANTIGEN 2; IMMEDIATE EARLY PROTEIN BZLF1; LATENT MEMBRANE PROTEIN 1; UNCLASSIFIED DRUG; VIRUS PROTEIN; VIRUS RNA;

ADOLESCENT; ARTICLE; B CELL LYMPHOMA; B LYMPHOCYTE; CELL MEMBRANE; CELL NUCLEUS; CHILD; CHILDHOOD CANCER; CLINICAL ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; CYTOPLASM; EPSTEIN BARR VIRUS; FEMALE; HERPES VIRUS INFECTION; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOCYTOCHEMISTRY; IN SITU HYBRIDIZATION; LATENT VIRUS INFECTION; LYMPHOCYTE TRANSFORMATION; MALE; NONHODGKIN LYMPHOMA; NONHUMAN; POLYMERASE CHAIN REACTION; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; VIRUS CARCINOGENESIS; VIRUS DETECTION; VIRUS LATENCY;

HUMAN HERPESVIRUS 4;

EID: 35548999640     PISSN: 02398508     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (38)

1. Roizman B. The family herpesviridae: general description, taxonomy, and classification. In: Roizman B, ed. The herpesviruses. New York. 1982:1-23.
2. Baumforth KRN, Young LS, Flavell KJ, Constandinou C, Murray PG. The Epstein-Barr virus and its association with human cancers. J Clin Pathol: Mol Pathol. 1999;52:307-322.
3. Jones JF, Shurin S, Abramowsky C et al. T-cell lymphomas containing Epstein-Barr viral DNA in patients with chronic Epstein-Barr virus infections. N Engl J Med. 1988;24:733-741.
4. Kobayashi I, Shima K, Saito I et al. Prevalence of Epstein-Barr virus in oral squamous cell carcinoma. J Pathol. 1999;189:34-39.
5. Sixbey JW, Davis DS, Young LS, Hutt-Fletcher L, Tedder TF, Rickinson AB. Human epithelial cell expression of an Epstein-Barr virus receptor. J Gen Virol. 1987;68:805-811.
6. Takada K. Role of Epstein-Barr virus in Burkitt's lymphoma. Curr Top Microbiol Immunol. 2001;258:141-151.
7. Kieff E, Rickinson AB. Epstein-Barr virus and its replication. In: Knipe DM, Howley PM, Griffin DE et al., eds. Fields' Virology, 4th ed., Philadelphia: Lippincott, Williams and Wilkins; 2001:2511-2573.
8. Wang F, Gregory C, Sample C et al. Epstein-Barr virus latent membrane protein (LMP1) and nuclear proteins 2 and 3C are effectors of phenotypic changes in B lymphocytes: EBNA-2 and LMP1 cooperatively induce CD23. J Virol. 1990; 64:2309-2318.
9. Tanner J, Weis J, Fearon D, Whang Y, Kieff E. Epstein-Barr virus gp350/ 220 binding to the B lymphocyte C3d receptor mediates adsorption, capping, and endocytosis. Cell. 1987; 50:203-213.
10. Prota AE, Sage DE, Stehle T, Fingeroth JD. The crystal structure of human CD21: implications for Epstein-Barr virus and C3d binding. Proc Natl Acad Sci USA. 2002;99:10641-10646.
11. Borza CM, Hutt-Fletcher LM. Alternate replication in B cells and epithelial cells switches tropism of Epstein-Baff virus. Nature Med. 2002;8:594-599.
12. Hochberg D, Middeldorp JM, Catalina M, Sullivan JL, Luzuriaga K, Thorley-Lawson DA. Demonstration of Burkitt's lymphoma Epstein-Barr virus phenotype in dividing latently infected memory cells in vivo. Proc Natl Acad Sci USA. 2004;101:239-244.
13. Kuppers R. B cell under influence: transformation of B cells by Epstein-Barr virus. Nature Rev. 2003;3:801-812.
14. Cordier-Bussat M, Billaud M, Calender A, Lenoir GM. Epstein-Barr virus (EBV) nuclear-antigen-2-induced up-regulation of CD21 and CD23 molecules is dependent on a permissive cellular context. Int J Cancer. 1993;53:153-160.
15. Dirmeier U, Neuhierl B, Kilger E, Reisbach G, Sandberg ML, Hammerschmidt W. Latent membrane protein 1 is critical for efficient growth transformation of human B cells by Epstein-Barr virus. Cancer Res. 2003;63:2982-2989.
16. Young LS, Murray PG. Epstein-Barr virus and oncogenesis: from latent genes to tumours. Oncogene. 2003;22:5108-5121.
17. Boyd AW, Fecondo J. Role of he CD21 antigen in lymphocyte transfromation by Epstein-Barr virus. Immunol Cell Biol. 1988;66:159-165.
18. Pillemer SR, Tsokos GC, Barbieri SA, Balow JE, Golding B. The CR2 receptor (CD21) shows increased expression in the more differentiated cells of an antigen-specific B cell line. Cell Immunol. 1990;125:386-395.
19. Shore A, Dosch HM, Gelfand EW. Expression and modulation of C3 receptors during early T-cell ontogeny. Cell Immunol. 1979;45:157-166.
20. Stevenson M, Volsky B, Hedenskog M, Volsky DJ. Immortalization of human T lymphocytes after transfection of Epstein-Barr virus DNA. Science. 1986;233:980-984.
21. Young LS, Sixbey JW, Clark D, Rickinson AB. Epstein-Barr virus receptors on human pharyngeal epithelia. Lancet. 1986; 1:240-242.
22. Hsu SM, Raine L, Fanger H. Use of avidin-biotin-peroxidase complex (ABC) in immunoperoxidase techniques. J Histochem Cytochem. 1981;29:577-580.
23. Kasprzak A, Zabel M, Wysocki J et al. Detection of DNA, mRNA and early antigen of the human cytomegalovirus (HCMV) using Immunomax technique in autopsy material of children with intrauterine infection. Virchows Arch. 2000; 437:482-490.
24. Remmele W, Stegner HE. Vorschlag zur einheitlichen Definition eines immunoreactiven Score (IRS) fur den Immunohistochemichen Ostrogenrezeptor - Nachweis (ER-ICA) im Mammakarzinomgewebe. Pathologie. 1987;8:138-140.
25. Habeshaw G, Yao QY, Bell AI, Morton D, Rickinson AB. Epstein-Barr virus nuclear antigen 1 sequences in endemic and sporadic Burkitt's lymphoma reflect virus strains prevalent in different geographic areas. J Virol. 1999;73:965-975.
26. Tao Q, Robertson KD, Manus, Hildesheim A, Ambinder RF. Epstein-Barr virus (EBV) in endemic Burkitt's lymphoma: molecular analysis of primary tumor tissue. Blood. 1998;91: 1373-1381.
27. Gregory CD, Rowe DM, Rickinson AB. Different Epstein-Barr virus (EBV) B cell interactions in phenotypically distinct clones of a Burkitt lymphoma cell line. J Gen Virol. 1990; 71:1481-1495.
28. Niedobitek G, Agathanggelou A, Rowe M et al. Heterogenous expression of Epstein-Barr virus latent proteins in endemic Burkitt's lymphoma. Blood. 1995;86:659-665.
29. Carbone A, Gloghini A. Expression of Epstein-Barr virus-encoded latent membrane protein 1 in nonendemic Burkitt's lymphomas. Blood. 1995;87:1202-1204.
30. Niedobitek G, Agathanggelou A, Herbst H, Whitehead L, Wright DH, Young LS. Epstein-Barr virus (EBV) infection in infectious mononucleosis: virus latency, replication and phenotype of EBV-infected cells. J Pathol. 1997;182:151-159.
31. Walling DM, Brown AL, Etienne W, Keitel WA, Ling PD. Multiple Epstein-Barr virus infection in healthy individuals. J Virol. 2003;77:6546-6550.
32. Idesawa M, Sugano N, Ikeda K et al. Detection of Epstein-Barr virus in saliva by real-time PCR. Oral Microbiol Immunol. 2004;19:230-232.
33. Cheung WY, Chan ACL, Loke SL et al. Latent sites of Epstein-Barr virus infection. Am J Clin Pathol. 1993;100: 502-506.
34. Hamilton-Dutoit SJ, Rea D, Raphael M et al. Epstein-Barr virus-latent gene expression and tumor cell phenotype in acquired immunodeficiency syndrome-related non-Hodgkin's lymphoma. Correlation of lymphoma phenotype with three distinct patterns of viral latency. Am J Pathol. 1993;143: 1072-1085.
35. Sugawara Y, Mizugaki Y, Uchida T et al. Detection of Epstein-Barr virus (EBV) in hepatocellular carcinoma tissue: a novel EBV latency characterized by the absence of EBV-encoded small RNA expression. Virology. 1999;256:196-202.
36. Kasprzak A, Spachacz R, Hałoń A et al. Tissue markers of Epstein-Barr virus (EBV) infection in B-cell non-Hodgkin's lymphomas. Med Wieku Rozwoj. 2006;X:639-648.
37. Cordier-Bussat M., Calender A, Vuillaume M, Bornkamm GW, Lenoir GM. Expression of the Epstein-Barr virus (EBV) latent membrane protein is tightly regulated, independently of EB; nuclear antigen 2 and of EBV integration or copy number. Virus Res. 1993;27:55-69.
38. van den Bosch CA. Is endemic Burkitt's lymphoma an alliance between three infections and a tumour promoter? Lancet. 2004;5:738-746.